search
Back to results

BIBR 277 Capsules in Hypertensive Patients With Nephropathy

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
BIBR 277
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Condition: Either of the following criteria is satisfied in laboratory tests:

    • Presence of a renal parenchymal disorder such as chronic glomerulonephritis is confirmed (serum creatinine < 3.0 mg/dL)
    • Presence of a renal function disorder (serum creatinine ≥ 1.5 mg/dL to < 3.0 mg/dL)
  • Age: ≥ 20 years
  • Sex: Either male or female
  • Patient status: Either outpatients or inpatients. However, the patient status should remain unchanged throughout the study period
  • Blood pressure (BP):

    • [Outpatients] The last 2 measurements of sitting BP out of at least 3 taken during the observation period (2 - 4 weeks) should be stable and a mean of the two measurements should be ≥160 mmHg for systolic BP (SBP) and ≥95 mmHg for diastolic BP (DBP)
    • [Inpatients] The last 2 measurements of supine BP taken during the observation period (1 week) should be stable and a mean of the 2 measurements should be ≥ 150 mmHg for SBP and ≥ 90 mmHg for DBP

Exclusion Criteria:

  • Renovascular hypertension
  • Undergoing haemodialysis
  • Severe hypertension (Diastolic BP ≥ 120 mmHg)
  • Severe heart failure, angina pectoris, or history of myocardial infarction
  • Atrioventricular conduction disturbance (degree II to III), atrial fibrillation, or serious arrhythmia
  • Symptoms of cerebrovascular disorder
  • Serious hepatic dysfunction
  • Uncontrolled diabetes
  • Peptic ulcer
  • History of hypersensitivity to drugs
  • Hyperkalaemia
  • Undergoing treatment with a digitalis preparation
  • Pregnant, breast feeding, possibly pregnant or planning to become pregnant during this study
  • Otherwise judged ineligible by the investigator

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Single rising doses of BIBR 277

    Arm Description

    Outcomes

    Primary Outcome Measures

    Changes from baseline in hypertensive effect by investigator, using a 5-grade classification

    Secondary Outcome Measures

    Changes from baseline in blood pressure reduction
    Rate of blood pressure normalisation
    percentage of patients with < 150/90 mmHg
    Changes from baseline in blood pressure / pulse rate
    Usefulness assessment by investigator, using a 5- grade classification
    Overall safety assessment by investigator, using a 5- grade classification
    Number of patients with adverse events
    Number of patients with abnormal changes in laboratory values

    Full Information

    First Posted
    July 9, 2014
    Last Updated
    July 9, 2014
    Sponsor
    Boehringer Ingelheim
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02187484
    Brief Title
    BIBR 277 Capsules in Hypertensive Patients With Nephropathy
    Official Title
    BIBR 277 Capsules Clinical Study on Hypertension With Nephropathy
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    August 1998 (undefined)
    Primary Completion Date
    August 1999 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boehringer Ingelheim

    4. Oversight

    5. Study Description

    Brief Summary
    The antihypertensive effect, safety and usefulness of treatment with BIBR 277 capsules were evaluated in hypertensive patients with nephropathy

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    23 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Single rising doses of BIBR 277
    Arm Type
    Experimental
    Intervention Type
    Drug
    Intervention Name(s)
    BIBR 277
    Primary Outcome Measure Information:
    Title
    Changes from baseline in hypertensive effect by investigator, using a 5-grade classification
    Time Frame
    8 weeks after start of treatment
    Secondary Outcome Measure Information:
    Title
    Changes from baseline in blood pressure reduction
    Time Frame
    8 weeks after start of treatment
    Title
    Rate of blood pressure normalisation
    Description
    percentage of patients with < 150/90 mmHg
    Time Frame
    8 weeks after start of treatment
    Title
    Changes from baseline in blood pressure / pulse rate
    Time Frame
    8 weeks after start of treatment
    Title
    Usefulness assessment by investigator, using a 5- grade classification
    Time Frame
    8 weeks after start of treatment
    Title
    Overall safety assessment by investigator, using a 5- grade classification
    Time Frame
    8 weeks after start of treatment
    Title
    Number of patients with adverse events
    Time Frame
    Up to 12 weeks
    Title
    Number of patients with abnormal changes in laboratory values
    Time Frame
    Up to 8 weeks after start of treatment

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    20 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Condition: Either of the following criteria is satisfied in laboratory tests: Presence of a renal parenchymal disorder such as chronic glomerulonephritis is confirmed (serum creatinine < 3.0 mg/dL) Presence of a renal function disorder (serum creatinine ≥ 1.5 mg/dL to < 3.0 mg/dL) Age: ≥ 20 years Sex: Either male or female Patient status: Either outpatients or inpatients. However, the patient status should remain unchanged throughout the study period Blood pressure (BP): [Outpatients] The last 2 measurements of sitting BP out of at least 3 taken during the observation period (2 - 4 weeks) should be stable and a mean of the two measurements should be ≥160 mmHg for systolic BP (SBP) and ≥95 mmHg for diastolic BP (DBP) [Inpatients] The last 2 measurements of supine BP taken during the observation period (1 week) should be stable and a mean of the 2 measurements should be ≥ 150 mmHg for SBP and ≥ 90 mmHg for DBP Exclusion Criteria: Renovascular hypertension Undergoing haemodialysis Severe hypertension (Diastolic BP ≥ 120 mmHg) Severe heart failure, angina pectoris, or history of myocardial infarction Atrioventricular conduction disturbance (degree II to III), atrial fibrillation, or serious arrhythmia Symptoms of cerebrovascular disorder Serious hepatic dysfunction Uncontrolled diabetes Peptic ulcer History of hypersensitivity to drugs Hyperkalaemia Undergoing treatment with a digitalis preparation Pregnant, breast feeding, possibly pregnant or planning to become pregnant during this study Otherwise judged ineligible by the investigator

    12. IPD Sharing Statement

    Links:
    URL
    http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.266_U04-3224.pdf
    Description
    Related Info

    Learn more about this trial

    BIBR 277 Capsules in Hypertensive Patients With Nephropathy

    We'll reach out to this number within 24 hrs